AffyImmune Therapeutics Inc logo

AffyImmune Therapeutics, Inc.

AffyImmune is an immuno-oncology startup developing T cell products based on proprietary CARs and TCRs technologies for treating solid tumors. AffyImmune has two products in pipeline, and are ready to commence clinical trials in 2018.

AffyImmune was founded based on intellectual property generated from Weill Cornell Medicine that enables imaging of T cells in patients and T cells to specifically target tumors.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.affyimmune.com
Founded
Disease Focus
Development Stage
STOCK CODENon Listed
Address
12 Michigan Drive Natick, MA 01760
Massachusetts
United States
Email
Contact Number
+1 617-699-1965

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

AffyImmunes proprietary technology may significantly improve the existing CAR-T cell therapy by extending the target of CAR-T therapies to solid tumors using a novel molecule and tuning down the affinity from picomolar to micromolar level to lower the on-target off-tumor toxicity.